The important cases observed at Pharmacovigilance Programme of India (PvPI) were disseminated to all its stakeholders and public at regular basis. In this article we discuss five such cases reported to the National Coordination Centre, Pharmacovigilance Programme of India (NCC-PvPI) from the ADR Monitoring Centre’s (AMCs) across the country. Toxic Epidermal Necrolysis (TEN) is also known as Lyell’s syndrome is uncommon but potentially life threatening Severe Cutaneous Adverse Reaction (SCAR) with widespread epidermal detachment and mucosal erosions. Sulfasalazine is the most common drug prescribed for many diseases, which causes many potential adverse reactions. TEN is one such adverse reaction and it may be fatal if not treated promptly. Early recognition and discontinuation of responsible drug remains primary treatment of management in drug induced TEN in our cases. The immediate treatment depends upon the severity of reaction. It is very much essential that patients should be educated regarding the medication so as to avoid future complications associated with drug use which can be achieved by creating awareness about such cases among all healthcare professionals.
Key words: Sulfasalazine, Toxic epidermal necrolysis, Pharmacovigilance programme of India, Disease-modifying antirheumatic drug.